Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Alexion Pharma

Biogen

Gilead Sciences

Moderna

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The short interest data is out for November 30, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Which Big Biotechs Short Sellers Favor Now

Cisco Systems

Goldman Sachs

Home Depot

JPMorgan Chase & Co

McDonald's

Merck

Microsoft

UnitedHealth Group

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration."- Dow Jones & Co. 30 Dow stocks represent nine of 11 sectors. Dow tracks utilities as a separate index and omits real estate. Broker top 10 target-estimated net gains ranged 11.05%-18.86% topped by MRK 12/7/20.

December Dogs Of The Dow Run Away

The FDA bestows a Breakthrough Therapy status on Amgen's (AMGN) KRAS inhibitor, sotorasib, for treating patients with advanced/metastatic non-small-cell lung cancer with KRAS G12C mutation.

Amgen's (AMGN) KRAS Inhibitor Gets Breakthrough Tag for NSCLC

Amgen Inc. (AMGN) Post ASH 2020 Oncology Update Conference (Transcript)

Amgen stock is down 5% since the start of the year and it has gained around 22% from its March lows. We believe that Amgen could offer an upside in the near term, as the company's revenues in the last three quarters have grown by 9%, primarily aided by its new drug Otezla.

Should You Buy Amgen Stock At $225?

THOUSAND OAKS, Calif., Dec. 5, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the first presentation of clinical safety and efficacy data from the Phase 1 study of AMG 701 in heavily pre-treated patients with relapsed/refractory multiple myeloma (R/R MM). AMG 701 is an...

Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020

Healthpeak Properties

Medtronic

Glenview Capital Management recently disclosed its portfolio updates for the third quarter of 2020, which ended on Sept. 30.

The Top New Health Care Buys of Larry Robbins' Firm

IRVING, Texas & THOUSAND OAKS, Calif.--(BUSINESS WIRE)--McKesson and Amgen (NASDAQ:AMGN), one of the world's leading biotechnology companies, have signed a strategic agreement to help improve cancer care in community oncology settings. Today, 1 in 5 cancer patients receives an Amgen medicine, while McKesson reaches 20% of U.S. cancer patients. This multi-year agreement bridges the power and reach of the two companies and will focus on reducing gaps in care by optimizing access to innovative pre

Amgen and McKesson Launch Strategic Agreement to Advance Cancer Innovation in Communities

Boston Scientific

Biotech stocks are vulnerable to headlines, but these three have too much potential to ignore. Own them for a swing trade into 2021.

3 Under-Loved Biotech Stocks to Buy for Profits Into 2021

Amgen's (AMGN) Management on Evercore ISI 3rd Annual HealthCONx Conference

Takeda Pharmaceutical

THOUSAND OAKS, Calif., Nov. 30, 2020 /PRNewswire/ -- Three members of the COVID R&D Alliance - Amgen Inc. (NASDAQ: AMGN), Takeda Pharmaceutical Co. Ltd. (NYSE: TAK), and UCB (Euronext BR: UCB) - today announced the first patient enrolled in the COMMUNITY Trial (COVID-19 Multiple Agents...

World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19

THOUSAND OAKS, Calif., Nov. 30, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, Dec. 5-8,...

Amgen Announces New Data Being Presented At ASH 2020

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Amgen (AMGN) Up 1.8% Since Last Earnings Report: Can It Continue?

Amgen is one of the world's largest independent biopharma companies, headquartered in California. The company's focus is recombinant DNA technology, with major product lines being immunostimulation medication, autoimmune diseases and others.

You Need To Look At Amgen - Right Now

THOUSAND OAKS, Calif., Nov. 25, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI Virtual HealthCONx Conference at 1:50 p.m. ET on Tuesday, Dec. 1, 2020. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive...

Amgen To Present At The Evercore ISI Virtual HealthCONx Conference

The short interest data are out for November 13, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Big Biotech Short Sellers Seek Cover

Salesforce

Johnson & Johnson

Dow 30,000 is great. But a Dow Jones at 31,659 is even better — and that's where the Blue Chip average is headed in 12 months, analysts say.

9 Stocks Seen Propelling Dow To 31,662

Cytokinetics

Amgen (AMGN) will terminate the collaboration with Cytokinetics and transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to the latter.

Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate

THOUSAND OAKS, Calif., Nov. 23, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Company has provided notice to Cytokinetics of termination of its collaboration and its intention to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594....

Amgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics

Amgen, Inc. (AMGN) Presents at Jefferies Virtual London Healthcare Broker Conference Call - (Transcript)

In trading on Wednesday, shares of Amgen crossed below their 200 day moving average of $231.90, changing hands as low as $230.26 per share. Amgen shares are currently trading down about 0.3% on the day.

Amgen Makes Notable Cross Below Critical Moving Average

Is Amgen (AMGN) a great pick from the value investor's perspective right now? Read on to know more.

Should Value Investors Pick Amgen (AMGN) Stock Right Now?

THOUSAND OAKS, Calif., Nov. 13, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Jefferies Virtual London Healthcare Conference at 12:00 p.m. ET on Wednesday, Nov. 18, 2020. Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the...

Amgen To Present At The Jefferies Virtual London Healthcare Conference

Duke Energy

Con Ed

Enterprise Products Partners

Realty Income Corp

Toronto-Dominion Bank

Tyson Foods

The Elephant Dividends portfolio's projected annual dividend income (PADI) is $907.25. Well-constructed charts and graphs are useful tools for monitoring and maintaining a properly diversified dividend portfolio.

Elephant Dividends Portfolio Monthly Review: October 2020

AbbVie

Anthem

Bristol-Myers

Cigna

As Mr. Valuation, I find myself constantly reminding investors that value investing requires patience. However, value investing also requires the willingness to get your money in front of attractive valuation when it is discovered. Trying to time your purchases perfectly can just as easily cause you to miss out on significant gains as it is to participate in them. More directly stated, significant undervaluation can stimulate strong pent-up demand causing stock prices to rise rapidly. Therefore, if you are not already in front of those advances, you can miss out on a lot of profit and opportunity.

News for Amgen Stock (AMGN)